Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck’s Niacin Combination Drug To Be Evaluated In Heart Protection Study 2

This article was originally published in The Pink Sheet Daily

Executive Summary

$79.2 mil. THRIVE study will evaluate niacin in combination with an investigational prostaglandin D2 blocker in 20,000 patients.

You may also be interested in...



Merck’s Simvastatin/Niacin Combination Delayed By Formulation Issues

Regulatory submission of the investigational HDL-raising, LDL-lowering fixed-dose combination, MK-0524B, had been planned for 2007.

Merck’s Simvastatin/Niacin Combination Delayed By Formulation Issues

Regulatory submission of the investigational HDL-raising, LDL-lowering fixed-dose combination, MK-0524B, had been planned for 2007.

Niaspan/Statin Combinations Improve Lipid Control, Study Shows

Addition of niacin to statin therapy demonstrates greater reductions in triglycerides and lipoprotein and increases in HDL-C.

Related Content

Topics

UsernamePublicRestriction

Register

PS064249

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel